Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs Kingsoft Cloud Holdings Limited — how do they compare? Adaptive Biotechnologies Corp trades at $20.06 (market cap $3.33B), while Kingsoft Cloud Holdings Limited trades at $10.61 (market cap $2.80B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | KC | |
|---|---|---|
Market Cap | $3.33B | $2.80B |
Sector | Health | Technology |
52-Week High | $22.37 | $18.21 |
52-Week Low | $10.24 | $8.58 |
Enterprise Value | $3.19B | $3.11B |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Kingsoft Cloud (KC) trades at $9.13 with a slight 0.33% daily gain, showing technical bearish signals despite recent earnings beats. The company reported $9.56B revenue for 2025 but continues to post net losses (-$936M), though AI-driven cloud demand is accelerating growth. Analyst sentiment remains positive with 70% buy ratings, while technical indicators show mixed signals with RSI levels suggesting potential oversold conditions.
KC presents a growth story fueled by AI cloud services expansion, but profitability challenges and negative margins create investor uncertainty. The stock's appeal hinges on management's ability to convert revenue growth into sustainable profits amid heavy infrastructure investments. Near-term catalysts include Q2 2026 earnings and margin improvement progress.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →